- Overview
- 150 Years
- News
- Biographies
- Speeches
- Photos
- TV Footage
- Publications
- Video Center
- Social Media Channels
- Apps
- Events
- Stories
- Media Contact
News
Friday - May 24, 2013
Not intended for U.S. and UK Media
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant more
Not intended for U.S. and UK Media
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant more
Friday - May 24, 2013
European Commission’s desision a set-back for European agriculture:
Decision to restrict use of neonicotinoid-containing products will not improve bee health more
European Commission’s desision a set-back for European agriculture:
Decision to restrict use of neonicotinoid-containing products will not improve bee health more
Friday - May 24, 20132013 ISF World Seed Congress in Athens
Bayer SeedGrowth™: the fully integrated system for on-seed applications from a single source
Around 100 years of experience in the seed treatment business / In-house competence in Products, Coatings, Equipment and Services / New customer-centric website www.seedgrowth.bayer.com launched more
Wednesday - May 22, 2013
Cemex Germany new cooperation partner:
Global specialist network for sustainable building grows
Over 80 specialists in Bayer-led EcoCommercial Building program more
Cemex Germany new cooperation partner:
Global specialist network for sustainable building grows
Over 80 specialists in Bayer-led EcoCommercial Building program more
Tuesday - May 21, 2013Novel ideas for mobility, construction and IT:
Bayer opens Innovation Hub for Asia Pacific
More than 200 experts to be employed in Shanghai more
Monday - May 20, 2013
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
SPECIALIZED PRESS
Not intended for U.S. and UK Media
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan more
Thursday - May 16, 2013
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands more
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands more
Thursday - May 16, 2013
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types more
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types more
Publications
Events
Wednesday, July 31, 2013
Q2 2013 Interim Report
Additional Press Events
Investor Relations Events
BayKomm Events
Q2 2013 Interim Report